Dr. David R. Pearson, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 292
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: Washington University School of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
MN license 64164 · PA license MD460085
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- M Health Fairview University of Mn Medical Center Minneapolis, MN
- M Health Fairview Southdale Hospital Edina, MN
- M Health Fairview Ridges Hospital Burnsville, MN
Medical groups
- Fairview Express Care (1,911 clinicians)
- University of Minnesota Health Clinics and Surgery Center Inc (617 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 292
- Services billed
- 1,319
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 329 | 58 |
| Established patient office or other outpatient visit, 20-29 minutes | 179 | 147 |
| Established patient office or other outpatient visit, 30-39 minutes | 96 | 67 |
| Destruction of precancer skin growth, 1 growth | 83 | 73 |
| Application of ultraviolet light to skin | 56 | 18 |
| Destruction of skin growth, 1-14 growths | 51 | 49 |
| New patient office or other outpatient visit, 30-44 minutes | 45 | 45 |
| Pathology examination of tissue using a microscope, intermediate complexity | 35 | 28 |
| Biopsy of related skin growth, first growth | 31 | 31 |
| Telephone medical discussion with physician, 11-20 minutes | 21 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Betamethasone Diprop Augmented (betamethasone/propylene glyc) | 146 |
| Triamcinolone Acetonide Other prescribers in Minneapolis, MN | 142 |
| Ketoconazole Other prescribers in Minneapolis, MN | 125 |
| Dupixent Pen (dupilumab) Other prescribers in Minneapolis, MN | 102 |
| Prednisone Other prescribers in Minneapolis, MN | 91 |
| Doxycycline Monohydrate Other prescribers in Minneapolis, MN | 71 |
| Clindamycin Phosphate Other prescribers in Minneapolis, MN | 67 |
| Hydroxychloroquine Sulfate Other prescribers in Minneapolis, MN | 63 |
| Mycophenolate Mofetil Other prescribers in Minneapolis, MN | 59 |
| Clobetasol Propionate Other prescribers in Minneapolis, MN | 58 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 11 payments worth $29,513 in total to this clinician.
| Merck Sharp & Dohme LLC | $23,634 |
|---|---|
| Pfizer Inc. | $3,734 |
| AstraZeneca UK Limited | $2,145 |
| Consulting Fee | $29,513 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Feb 3, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $7,875 |
| Merck Sharp & Dohme LLC May 12, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $5,875 |
| Merck Sharp & Dohme LLC Aug 13, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $4,125 |
| Merck Sharp & Dohme LLC Jan 13, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $3,250 |
| Pfizer Inc. Jun 30, 2025 | Consulting Fee | $2,175 |
| AstraZeneca UK Limited Jul 4, 2025 | Consulting Fee | $2,145 |
| Pfizer Inc. Aug 25, 2025 | Consulting Fee | $1,559 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,294 |
| Merck Sharp & Dohme LLC May 19, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $675 |
| Merck Sharp & Dohme LLC Feb 10, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $290 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Oct 15, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $250 |
| Pfizer Inc. Aug 25, 2025 | Consulting Fee | $1,559 |
| Merck Sharp & Dohme LLC Aug 13, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $4,125 |
| AstraZeneca UK Limited Jul 4, 2025 | Consulting Fee | $2,145 |
| Pfizer Inc. Jun 30, 2025 | Consulting Fee | $2,175 |
| Merck Sharp & Dohme LLC May 19, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $675 |
| Merck Sharp & Dohme LLC May 12, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $5,875 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,294 |
| Merck Sharp & Dohme LLC Feb 10, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $290 |
| Merck Sharp & Dohme LLC Feb 3, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $7,875 |
| Merck Sharp & Dohme LLC Jan 13, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $3,250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $14,440 in research payments for these studies, mostly to the institutions running them.
- A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Daiichi Sankyo Inc. · Completed · NCT05638802
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.